Contact Us: 1-518-583-0095 
We’re Hiring… Join Our Team!
Hemostemix, a clinical-stage Canadian-Israeli company developing innovative blood-derived cell therapies for severe medical conditions, announced today the kick-off of a services collaboration with Criterium Inc. as its clinical research organization (CRO) for the company’s phase 2 clinical trial in critical limb ischemia.
Continue readingThis is a study to evaluate the safety and pharmacokinetics profile of different doses of AB‐103 administered to patients diagnosed with Necrotizing Soft Tissue Infections that are scheduled for an urgent surgical intervention as part of their standard of care.
Continue readingPharmaceutical and biotechnology major Wockhardt has received final approval from the United States Food & Drug Administration (US FDA) for marketing 50 mcg nasal spray of Fluticasone which is used in treatment of allergic rhinitis.
Continue readingCriterium, Inc., a full-service, global CRO, is pleased to announce the acquisition of the former Aptium Oncology’s CORE Science Solutions (CSS) Cancer Consortium Groups consisting of AGICC and AMyC as the newest members of Criterium’s Pharma services companies.
Continue readingCriterium, Inc., a full-service Global CRO is pleased to announce its 20th Anniversary, a span in which it has been providing superior clinical trial and support services to sponsors.
Continue readingCriterium, Inc., a full-service CRO is expanding client service offerings by including an “a la carte” style of pricing to allow clients to create the individualized clinical trials experience that most exactly suits their needs.
Continue readingCriterium, Inc., a full-service CRO is pleased to announce its newest global office located in Toronto.
Continue readingIn this study Criterium is providing Indian regulatory expertise, recruiting sites that will screen, enroll, register and randomize 740 patients at investigational sites representing every region in India, monitoring the study, designing and validating the case report forms, managing and analyzing the data, and writing the final clinical study report.
Continue readingCriterium, Inc., the full service, global, technology driven contract research organization announced today that after successfully working with OmniComm Systems, Inc. on several clinical studies, it has chosen OmniComm’s TrialMaster™ Electronic Data Capture (EDC) solution as its commercial EDC of choice.
Continue readingCriterium, Inc. announces that it has been selected over competing vendors by Ichor Medical Systems to participate in a Phase Ia/Ib clinical trial that will involve a novel delivery technology and a proprietary melanoma vaccine.
Continue reading